Favorite

EpiPen lesson 

Congressional Republicans and Democrats staged a rousing display of rage against the CEO whose company gouged a fortune from families whose kids and sometimes grownups need the lifesaving properties of the drug EpiPen.

The national fury over the fleecing of sick children by Mylan N.V., which bought the rights to the allergy antidote and jacked up the price of a dose from $57 to $600, followed by the Mylan executive's rough treatment in Congress, caused some wonder. Could Washington at long last be spurred to do something about the chief driver of staggering health care inflation?

Don't be silly. Congress will do nothing of the sort. It and successive presidents have squandered every golden opportunity, including passage of two sweeping health-reform laws, the Medicare Modernization Act of 2003 and the Patient Protection and Affordable Care Act of 2010, a.k.a. Obamacare. Like previous laws, they imposed cost-saving rules on providers and insurers, but to get anything enacted Congress gave the drug companies a pass.

Since 1995, premiums for health plans have risen four times faster than family earnings and five times faster than inflation, owing mostly to drug prices and especially those of lifesaving medicine where drug companies know the market will bear any price hike.

Government, in the persons of Congress, the Food and Drug Administration and the Department of Health and Human Services, actually assists the gouging by approving bigger prescriptions — a mandatory twin pack in the case of EpiPen — or, also in the case of EpiPen, requiring many schools to stock them for emergencies. EpiPens have a brief shelf life so they must constantly be replaced. Mylan got Congress to provide block grants to states to stock EpiPens in schools.

Insurance companies merely raise premiums to cover the soaring costs. When Congress passed Medicare coverage for drugs in 2004, it defeated attempts by a few Democrats, including East Arkansas's Marion Berry, to control drug prices. Congress even barred the government from negotiating discounts for mass usage or from acquiring drugs in Europe or Canada where prices are far lower.

As critical cancer drugs went on the market the past 15 years, prices soared. A new cancer drug may cost a patient or her insurer more than $100,000 a year. Employer and individual plans often don't cover them. Cancer drugs are a leading cause of bankruptcies.

You may remember the furor last year after the egomaniac Martin Shkreli's company bought rights to a drug for a parasitic infection that was deadly for babies and AIDS sufferers. Shkreli became a symbol of Big Pharma greed when he raised the price of the drug, which had been around for decades, from $13.50 to $750 for one tablet. Shkreli, CEO of Turing Pharmaceuticals, regretted not raising it even more because people had to buy it or probably die. There was some satisfaction when the U.S. attorney in Brooklyn had Shkreli arrested. But his arrest had nothing to do with exploiting sick people. He was charged with securities fraud because he used drug profits to pay off investors who had lost money with his hedge fund.

To understand why no one messes with pharmaceutical profits, except to complain occasionally, you only have to switch on any TV channel and watch commercials for an hour. You know who pays the freight for public discourse.

Congressmen scored some points against EpiPen's blithe chief saleswoman, CEO Heather Bresch, but in the end it was her day, not theirs. The super-polite Rep. Elijah Cummings, D-Md., asked Bresch if she could confirm that her base annual salary was $18.9 million and that the EpiPen alone brought profits of "hundreds and hundreds of millions of dollars a year" for her company. She replied sweetly, yes and yes.

While Mylan was jacking up EpiPen's price annually, Bresch's salary went from $2.4 million to $18.9 million. Mylan's income was spent on more than executive pay. It spent lavishly on ads to promote what it called "increased anaphylaxis awareness": persuading people they needed easy access to EpiPens to avert their allergic child's sudden death.

Maybe a new president and Congress will be different. Donald Trump sided with Democrats on letting Medicare and Medicaid negotiate with drug companies and buy drugs from countries with socialized medicine, but otherwise he says only that he'll solve the problem as soon as he repeals Obamacare and ends health insurance for 20 million people. Big Pharma flushed lots of money into presidential campaigns, Hillary Clinton's more than any other, but she has been more critical than others of the whopping prices of generic and new drugs. She laid out a long list of things she would do to control drug prices, including getting Congress to levy stiff fines on companies that raise prices unjustifiably and importing vital drugs from countries with high safety standards.

You read it here first. None of it will happen.

Favorite

Sign up for the Daily Update email

Speaking of EpiPen

  • The lesson of EpiPen

    September 27, 2016
    Ernest Dumas this weeks writes about the high-priced  EpiPen and it's symbolism for a Congress controlled by drug makers, as well as rising health care costs /more/
  • More »

Comments

Subscribe to this thread:

Add a comment

More by Ernest Dumas

  • Week That Was

    After the wildest week of the wildest presidency in history, the clouded future suddenly unfolds more clearly and, yes, nearer. That includes the end of the Trump presidency.
    • Apr 19, 2018
  • The pathetic fallacy

    What do you call an idea that grows in popularity the more it is proven wrong? Let's steal John Ruskin's literary term, "the pathetic fallacy," because it is more descriptive than his use of it.
    • Apr 12, 2018
  • Teachers and tax cuts

    In a year of odd phenomena, none is odder than this: Across the nation's midsection, schoolteachers are suddenly fed up with their government's treatment of education and educators, and Republican governors and legislatures are capitulating right and left, even raising taxes to mollify them.
    • Apr 5, 2018
  • More »

Readers also liked…

  • Along the civil rights trail

    A convergence of events in recent days signaled again how far we have come and how far we have yet to go in civil rights.
    • Jan 18, 2018
  • The Oval outhouse

    One thing all Americans finally can agree upon is that public discourse has coarsened irretrievably in the era of Donald Trump and largely at his instance.
    • Jan 18, 2018
  • Shrugging off sulfides

    The Arkansas Democrat-Gazette reported a shocker on its front page Sunday. The rotten-egg odor from the Koch brothers' sprawling paper plant at Crossett is still making people sick, but the state's pollution control agency is unaware of the problem.
    • Mar 29, 2018

Latest in Ernest Dumas

  • Week That Was

    After the wildest week of the wildest presidency in history, the clouded future suddenly unfolds more clearly and, yes, nearer. That includes the end of the Trump presidency.
    • Apr 19, 2018
  • The pathetic fallacy

    What do you call an idea that grows in popularity the more it is proven wrong? Let's steal John Ruskin's literary term, "the pathetic fallacy," because it is more descriptive than his use of it.
    • Apr 12, 2018
  • Teachers and tax cuts

    In a year of odd phenomena, none is odder than this: Across the nation's midsection, schoolteachers are suddenly fed up with their government's treatment of education and educators, and Republican governors and legislatures are capitulating right and left, even raising taxes to mollify them.
    • Apr 5, 2018
  • More »

Most Viewed

  • Redefining candidate quality

    Despite what national party organizations like the Democratic Congressional Campaign Committee and the National Republican Campaign Committee say, conventional definitions of candidate quality are not leading to progressive wins in 2018.

Most Recent Comments

  • Re: Redefining candidate quality

    • "It's the grassroots fire that ignited in the days and weeks after President Trump's election…

    • on April 20, 2018
  • Re: Week That Was

    • I saw James Comey interviewed by Stephen Colbert. When Stephen asked if trump was mentally…

    • on April 20, 2018
  • Re: Trump and Comey

    • Oh, so now it was the Comey release of the e-mails before the election to…

    • on April 19, 2018
 

© 2018 Arkansas Times | 201 East Markham, Suite 200, Little Rock, AR 72201
Powered by Foundation